The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV. The main questions it aims to answer are: 1. Is bone mass deterioration is significant even with the new medication currently used to treat HIV? 2. Can one dose of Zolendric acid protect from deterioration of bone mass. Researchers will compare one dose of zolendric acid to follow-up only Participant will: 1. Provide blood samples for bone markers before antiviral treatment initiation and at 6M,12M,24M and 48M after treatment initiation 2. Perform DXA scan soon after antiviral treatment initiation and after 12M ,24 M and 48 months 3. Half of the patients with moderate reduction in bone mass will be treated with one dose of zolendric acid in the clinical trial, the other participants will be followed without intervention. 4. Patients with substantial osteoporosis will be treated according to standard of care by their HMO, but will continue followup in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
110
Zolendric acid will be provided to HIV naïve patients with documented osteopnia
Rambam Medical Center
Haifa, Israel
NOT_YET_RECRUITINGHadassah Hebrew University Medical Center
Jerusalem, Israel
RECRUITINGSheba Medical Center
Ramat Gan, Israel
NOT_YET_RECRUITINGBone density at 12 months.
Average change (in %) from baseline in spine T score and hip T-score values among participants in the intervention group versus participants in the control group at 12 months after ART initiation
Time frame: 12 months of initiation of ART
Bone density at 24 months.
Average change (in %) from baseline in spine T score and hip T-score values among participants in the intervention group versus participants in the control group at 24. ART.
Time frame: 24 months
Bone density at 48 months.
Average change (in %) from baseline in spine- and hip T-score values among participants in the intervention group versus participants in the control group at 48 months of initiation of ART.
Time frame: 48 months of initiation of ART
Bone fractures at 48 months
To estimate the rates of clinical fractures among all participants over a minimum of 48 months and the difference, if any, between treatment arms.
Time frame: 48 months of initiation of ART
Bone markers differences during folloe up
Identify difference in average blood levels of bone turnover markers between treatment arm and the non intervention arm during the follow-up period.
Time frame: 6,12,24,48 months after treatment intiation
BMD decline in TDF sparing ART
Rates of BMD decline (by means of rate of naïve PLHIV with baseline T score \> -1.0 who will turn to T score \<-1.0) in PLHIV treated with TDF-sparing ART over a period of 48 months.
Time frame: 48 months of initiation of ART
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.